Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indicationsPURCHASE, N.Y.,...
Month: November 2021
Day One to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Fountain Therapeutics Announces $15 Million Series A-2 Financing
Brings total Series A financing to $26 million Funds to support expansion of leadership team, continued R&D activities and pre-clinical...
SOTIO Strengthens its Strategic Advisory Board with Esteemed Oncology Experts and Industry Veterans
PRAGUE, Czech Republic, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group,...
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed...
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company...
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per yearMIAMI, Nov. 18, 2021...
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight
Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposalsMONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE)...
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing...
Clarapath, Medical Robotics Company, Raises $32M in Additional Funding
Closing 100 Year-Old Missing Link: Dramatically Improves Pathology Workflow with Intelligent Robotics and Utilizes Proprietary Inputs for Next-Gen Precision Medicine...
Simply Better Brands Corp. Announces USD$2.6 Million Monthly Revenue For October 2021 Driven by Accelerated Customer Acquisition
VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC)...
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development programNEW HAVEN, Conn.,...
Abeona Therapeutics Announces Support of EB Research Partnership’s Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene...
EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
Anticipate Submission for Label Extension in First Half 2022YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD)...
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most...
BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
-Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund...
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering...
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...
CLS Again Releases TRANBERG® Sterile Disposable Products into the US Market
IRVINE, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal...
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic...
